Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small …
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment Read More